Brief Title
Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
Official Title
Cerebellar Transcranial Magnetic Stimulation for Motor Control in Progressive Supranuclear Palsy
Brief Summary
The objective of this proposal is to investigate the effect of non-invasive repetitive
cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive
supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via
cerebellar rTMS will decrease postural instability in patients with PSP by increasing
functional connectivity between the cerebellum, thalamus, and primary motor cortex.
Study Type
Interventional
Primary Outcome
objective posturography
Secondary Outcome
fMRI correlations
Condition
Palsy Supranuclear
Intervention
Repetitive transcranial magnetic stimulation (rTMS)
Study Arms / Comparison Groups
Active TMS first
Description: After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week TMS intervention. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week sham TMS period prior to their final assessment.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
30
Start Date
January 17, 2020
Completion Date
June 2026
Primary Completion Date
January 2026
Eligibility Criteria
Inclusion Criteria:
- probable or possible PSP by the revised MDS PSP Criteria (Hoglinger 2017)
- age 40-85 at time of screening
- ability to understand and cooperate with simple instructions in English
- ability to read at 6th grade reading level in English
- ability to stand unassisted for at least 30 seconds and to be able walk independently
with a walker
- ability to refrain from new physical and speech therapy programs for the duration of
the study
- ability to remain on stable doses of any cholinergic, dopaminergic, serotonergic
sedative or NMDA receptor antagonists for the duration of the study
- females of child-bearing age must perform a urine pregnancy test and be on reliable
birth control during the course of the study
Exclusion Criteria:
- other significant neurological or vestibular disorders
- presence of electrically, magnetically or mechanically activated implants or history
of injurious metal exposure in eyes, head, or body
Gender
All
Ages
40 Years - 85 Years
Accepts Healthy Volunteers
No
Contacts
Marian L Dale, MD, MCR, 5034182601, [email protected]
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT04468932
Organization ID
STUDY0020341
Secondary IDs
KL2TR002370
Responsible Party
Principal Investigator
Study Sponsor
Oregon Health and Science University
Collaborators
National Center of Neuromodulation for Rehabilitation
Study Sponsor
Marian L Dale, MD, MCR, Principal Investigator, Oregon Health and Science University
Verification Date
May 2022